Avalo Therapeutics, Inc. (AVTX) Financials

AVTX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 99.9 million 31.6 million
Dec. 31, 2025 116.5 million 33.4 million
Sept. 30, 2025 125.1 million 33.6 million
June 30, 2025 126.6 million 22.0 million

AVTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -17.7 million 3.6 million
Dec. 31, 2025 -14.2 million 4.5 million
Sept. 30, 2025 -16.4 million 3.2 million
June 30, 2025 -11.4 million 2.7 million

AVTX Net Income

No data available :(

AVTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 82.0 million 2.0 million -
Dec. 31, 2025 98.3 million 2.0 million 427000
Sept. 30, 2025 111.6 million - 555000
June 30, 2025 113.3 million - 679000

AVTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 20.1 million
Dec. 31, 2025 13.4 million
Sept. 30, 2025 14.0 million
June 30, 2025 10.8 million

AVTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 14.0 million 6.8 million -
Dec. 31, 2025 - 13.3 million 6.5 million 381000
Sept. 30, 2025 - 13.6 million 5.6 million 22000
June 30, 2025 - 14.1 million 5.2 million 56000

AVTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 17000
Dec. 31, 2025 59000 16000
Sept. 30, 2025 - -
June 30, 2025 - 134000

AVTX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

AVTX

Price: $14.76

52 week price:
4.06
24.27

Earnings Per Share: -5.57 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 45800

Market Capitalization: 157.7 million

Links: